Here we explored the therapeutic benefit of combining everolimus to a PARP inhibitor in two different patient-derived xenografts of BRCA2-mutated breast cancer with genomic alterations in the PI3K pathway. This evidence concerns the gene PARP1 and breast carcinoma.